Cargando…
P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Autores principales: | Popat, R, Usmani, S, Garfall, A, van de Donk, N, Nahi, H, San-Miguel, J, Oriol, A, Nooka, A, Martin, T, Rosinol, L, Chari, A, Karlin, L, Benboubker, L, Mateos, M, Bahlis, N, Moreau, P, Besemer, B, Martínez-López, J, Sidana, S, Pei, L, Trancucci, D, Verona, R, Girgis, S, Olyslager, Y, Jaffe, M, Uhlar, C, Stephenson, T, Van Rampelbergh, R, Banerjee, A, Goldberg, J, Kobos, R, Krishnan, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009794/ http://dx.doi.org/10.1097/01.HS9.0000829596.42296.29 |
Ejemplares similares
-
P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Martínez-López, J., et al.
Publicado: (2022) -
P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Popat, R., et al.
Publicado: (2022) -
P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Sidana, Surbhi, et al.
Publicado: (2023) -
P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023) -
P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)